{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/idxx-stock-analysis/",
 "dataUrl": "https://clearank.com/stock/idxx-stock-analysis/data.json",
 "title": "IDEXX (IDXX) Stock Forecast & Price Target (2026)",
 "description": "IDEXX Laboratories, Inc. (IDXX) stock: Healthcare, Diagnostics & Research. $41.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "IDEXX Laboratories, Inc. (IDXX)",
 "published": "2026-07-19T09:40:34+00:00",
 "modified": "2026-09-27T03:00:54.166+00:00",
 "generated": "2026-09-27T15:54:19.291Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "IDXX",
  "name": "IDEXX Laboratories, Inc.",
  "type": "Common Stock",
  "exchange": "NASDAQ",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Diagnostics & Research",
  "country": "United States",
  "website": "https://www.idexx.com"
 },
 "quote": {
  "price": 519.26,
  "previousClose": 513.39,
  "change": 5.87,
  "changePercent": 1.14,
  "open": 510.94,
  "high": 520.15997,
  "low": 507.01001,
  "volume": 331100,
  "averageVolume": 503090,
  "marketCap": 40960785811,
  "fiftyTwoWeekHigh": 769.97998,
  "fiftyTwoWeekLow": 500.60999,
  "marketOpen": false,
  "asOf": "2026-09-27T03:00:54.000Z"
 },
 "statistics": {
  "pe": 36.4393,
  "eps": 14.25,
  "dividendYield": 0,
  "beta": 1.538,
  "priceToSales": 8.995998,
  "priceToBook": 25.397898,
  "revenueTtm": 4553223168,
  "grossMargin": 0.6403884644311741,
  "returnOnEquity": 0.74211
 },
 "technicals": {
  "rsi": 39.5,
  "macd": -9.33,
  "sma50": 546.74,
  "sma200": 592.41,
  "rsiSignal": "Bearish",
  "trend": "Bearish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Hold",
  "score": 59,
  "consensus": "Hold",
  "fairValue": 519.26,
  "analystTarget": 700,
  "analystCount": 14,
  "wallStreetConsensus": "Hold",
  "generatedAt": "2026-09-27T03:00:54.000Z",
  "priceAtAnalysis": 519.26001,
  "volatility": {
   "daily": 1.42,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Neutral",
  "conservativeEntry": 514.07,
  "aggressiveEntry": 519.26,
  "stopLoss": 494.07,
  "stopLossPercent": 3.89,
  "targets": [
   529.49,
   539.77,
   555.19
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 380.9,
    "base": 578.97,
    "upside90th": 880.05
   },
   {
    "year": 2028,
    "downside10th": 357.07,
    "base": 645.54,
    "upside90th": 1167.08
   },
   {
    "year": 2029,
    "downside10th": 348.52,
    "base": 719.78,
    "upside90th": 1486.52
   },
   {
    "year": 2030,
    "downside10th": 347.35,
    "base": 802.54,
    "upside90th": 1854.25
   },
   {
    "year": 2031,
    "downside10th": 350.84,
    "base": 894.83,
    "upside90th": 2282.27
   },
   {
    "year": 2032,
    "downside10th": 357.74,
    "base": 997.72,
    "upside90th": 2782.59
   },
   {
    "year": 2033,
    "downside10th": 367.41,
    "base": 1112.45,
    "upside90th": 3368.29
   },
   {
    "year": 2034,
    "downside10th": 379.49,
    "base": 1240.37,
    "upside90th": 4054.15
   },
   {
    "year": 2035,
    "downside10th": 393.8,
    "base": 1383,
    "upside90th": 4857.04
   },
   {
    "year": 2036,
    "downside10th": 410.23,
    "base": 1542.03,
    "upside90th": 5796.32
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "IDXX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$510.94",
    "Day Range": "$507.01 to $520.16",
    "Prev Close": "$513.39",
    "Volume": "331.1K",
    "52-Week Range": "$500.61 to $769.98",
    "Market Cap": "$40.96B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Valuation is broadly in line with sector peers (14% difference), suggesting fair market pricing relative to industry standards."
   ]
  },
  {
   "id": "financials",
   "title": "IDXX Financial Performance",
   "text": [
    "Analysis: In the last 4 quarters, IDXX beat estimates 4 times. However, the stock fell 3 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "IDXX Analysis",
   "text": [
    "IDEXX Laboratories is trading below its 50-day SMA of $546.74 and its 200-day SMA of $592.41, indicating a bearish trend. The RSI is at 39.5, reflecting bearish momentum, and the MACD is at -9.33, further supporting a negative technical outlook. The stock is also below its 20-day EMA of $523.68. The current price action suggests downward pressure. Volume was 34.2% below average on the latest trading day, indicating reduced investor interest. The chart structure points towards continued weakness unless a significant bullish catalyst emerges.",
    "Insiders have sold over $75.1 million worth of IDXX stock with no reported purchases, indicating a strong net selling signal that could weigh on future price performance.",
    "The stock is currently positioned below its 50-day SMA ($546.74) and 200-day SMA ($592.41), suggesting a bearish technical trend and potential for further downside.",
    "The median analyst price target for IDXX is $700, suggesting a potential upside of 34.8% from the current trading price, indicating analyst confidence in future appreciation.",
    "IDEXX Laboratories consistently delivers strong profit margins (25.03%) and a high return on equity (74.21%), outperforming sector averages and demonstrating operational efficiency.",
    "The base case for IDEXX Laboratories over the next 6-12 months anticipates a potential recovery towards the median analyst target price of $700, representing a 34.8% upside from the current price. This outlook is supported by the company's strong historical growth, strong profit margins, and positive forward-looking revenue estimates, with current year revenue growth projected at 10.00% and next year at 9.00%. However, the thesis could be challenged by continued insider selling and a failure to break above key technical resistance levels. Downside risks include a potential valuation reset if growth slows or competitive pressures intensify, which could lead to a retest of lower support levels. Any positive catalyst, such as a significant new product launch or a shift in insider sentiment, could accelerate upside potential."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transactions closely; the current heavy net selling by insiders warrants significant attention and could signal management's short-term concerns.",
     "Pay attention to the 50-day and 200-day moving averages as key indicators of trend direction; a sustained break above these levels would be a bullish signal.",
     "Given the premium valuation, any signs of slowing revenue growth or increased competition could negatively impact the stock price."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold over $75.1 million worth of IDXX stock with no reported purchases, indicating a strong net selling signal that could weigh on future price performance.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Trading Below Key Moving Averages",
     "text": "The stock is currently positioned below its 50-day SMA ($546.74) and 200-day SMA ($592.41), suggesting a bearish technical trend and potential for further downside.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bullish",
     "title": "Positive Analyst Price Targets",
     "text": "The median analyst price target for IDXX is $700, suggesting a potential upside of 34.8% from the current trading price, indicating analyst confidence in future appreciation.",
     "source": "Wall Street Analysts"
    },
    {
     "type": "Bullish",
     "title": "Strong Profitability and ROE",
     "text": "IDEXX Laboratories consistently delivers strong profit margins (25.03%) and a high return on equity (74.21%), outperforming sector averages and demonstrating operational efficiency.",
     "source": "Company Fundamentals"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "IDEXX Laboratories exhibits a P/E ratio of 36.44, which is above the sector median of 31.9, suggesting a premium valuation relative to peers. Its price-to-sales ratio stands at 9.00, also higher than the sector median of 3.7. The company boasts a strong profit margin of 25.03% and an impressive return on equity of 74.21%, significantly outperforming the sector's ROE of 6.9%. While the company's profitability and efficiency metrics are strong, the current valuation appears stretched when compared to sector averages. The debt-to-equity ratio of 0.68 is within reasonable bounds, but the premium valuation combined with recent technical weakness and insider selling warrants a cautious approach.",
    "IDEXX Laboratories most recently reported earnings for the quarter ending June 2026, with EPS of $4.27, beating estimates of $3.93 by 8.65%. This followed a pattern of positive EPS surprises in prior quarters, though the quarter ending December 2025 showed a significant miss. Revenue growth for the current quarter is estimated at +8.00% year-over-year, with full-year revenue growth projected at +10.00%.",
    "The primary risk for IDEXX Laboratories stems from significant insider selling, with over $75.1 million in sales and no reported purchases, indicating potential concerns among management. Additionally, the stock is trading below key technical indicators like the 50-day and 200-day SMAs, suggesting a bearish trend and potential for further price declines. The premium valuation relative to sector averages also presents a risk if growth expectations are not met."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "40.96B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "36.44"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "14.25"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "769.98"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "500.61"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Bearish SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $546.74, 200-day: $592.41), price is trading below the 50-day SMA."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "39.50"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-9.33"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "546.74"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "592.41"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.43",
    "Correlation with Nasdaq 100 (QQQ)": "+0.36",
    "Correlation with Bitcoin (BTC)": "+0.09",
    "Correlation with Gold (XAU)": "+0.09"
   }
  },
  {
   "id": "trade-plans",
   "title": "IDXX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Enter now if confident",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (39.5) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$529.49",
    "TARGET 2": "$539.77",
    "TARGET 3": "$555.19",
    "STOP LOSS": "$494.07"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+3.48%",
    "Average Feb return": "+2.18%",
    "Average Mar return": "-1.63%",
    "Average Apr return": "+2.21%",
    "Average May return": "+3.18%",
    "Average Jun return": "+2.75%",
    "Average Jul return": "+6.79%",
    "Average Aug return": "+1.91%",
    "Average Sep return": "-2.87%",
    "Average Oct return": "-1.08%",
    "Average Nov return": "+3.07%",
    "Average Dec return": "+1.10%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "1.42%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in IDXX in September 2016 would be worth about $45,843 today, compared with about $35,782 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IDXX today could grow to about $29,697 by 2036 in the base case, with a bull case near $111,627 and a bear case around $7,900. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "IDXX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $803 for IDXX by 2030 in the base case, from $519 today (1.5x over 4 years). The downside path ends near $347. These are outcomes of a Monte Carlo simulation run on IDXX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using IDXX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "IDXX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$381",
        "$579",
        "$880"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$357",
        "$646",
        "$1,167"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$349",
        "$720",
        "$1,487"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$347",
        "$803",
        "$1,854"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$351",
        "$895",
        "$2,282"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$358",
        "$998",
        "$2,783"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$367",
        "$1,112",
        "$3,368"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$379",
        "$1,240",
        "$4,054"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$394",
        "$1,383",
        "$4,857"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$410",
        "$1,542",
        "$5,796"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "AGL agilon health, Inc. NYSE $80.73 +6.46%",
     "url": "https://clearank.com/stock/agl-stock-analysis/"
    },
    {
     "text": "MOH Molina Healthcare Inc. NYSE $190.86 -1.27%",
     "url": "https://clearank.com/stock/moh-stock-analysis/"
    },
    {
     "text": "JNJ Johnson & Johnson NYSE $271.22 +0.20%",
     "url": "https://clearank.com/stock/johnson-johnson-jnj/"
    },
    {
     "text": "REGN Regeneron Pharmaceuticals, Inc. NASDAQ $788.04 -1.00%",
     "url": "https://clearank.com/stock/regeneron-regn/"
    },
    {
     "text": "CAPR Capricor Therapeutics, Inc. NASDAQ $8.36 -2.45%",
     "url": "https://clearank.com/stock/capr-stock-analysis/"
    },
    {
     "text": "CI The Cigna Group NYSE $272.01 +2.45%",
     "url": "https://clearank.com/stock/cigna-group-ci/"
    },
    {
     "text": "ILMN Illumina Inc. NASDAQ $270.00 -1.42%",
     "url": "https://clearank.com/stock/ilmn-stock-analysis/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.44 +3.06%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Popular Comparisons",
   "links": [
    {
     "text": "IONQ vs RGTI Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/ionq-vs-rgti/"
    },
    {
     "text": "Gold vs Bitcoin Analysis and Targets Head-to-head analysis →",
     "url": "https://clearank.com/compare/gold-vs-bitcoin/"
    },
    {
     "text": "LLY vs ABBV Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/lly-vs-abbv/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "IDXX Insider Trading Analysis",
   "facts": {
    "Bought": "None",
    "Sold": "$75.1M",
    "Insiders": "17",
    "Avg Transaction": "$4.2M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in IDXX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Aug 14, 2020",
       "cells": [
        "MCKEON BRIAN P Chief Financial Officer",
        "Sell",
        "83.7K",
        "$31.7M"
       ]
      },
      {
       "label": "Aug 6, 2025",
       "cells": [
        "MAZELSKY JONATHAN JAY Chief Executive Officer",
        "Sell",
        "29.3K",
        "$18.5M"
       ]
      },
      {
       "label": "Aug 17, 2020",
       "cells": [
        "AYERS JONATHAN W Director",
        "Sell",
        "44.9K",
        "$17.1M"
       ]
      },
      {
       "label": "Nov 4, 2020",
       "cells": [
        "MCKEON BRIAN P Chief Financial Officer",
        "Sell",
        "36.2K",
        "$17.1M"
       ]
      },
      {
       "label": "Feb 26, 2026",
       "cells": [
        "MAZELSKY JONATHAN JAY Chief Executive Officer",
        "Sell",
        "23.3K",
        "$15.3M"
       ]
      },
      {
       "label": "May 12, 2020",
       "cells": [
        "AYERS JONATHAN W Director",
        "Sell",
        "50.0K",
        "$14.8M"
       ]
      },
      {
       "label": "Aug 4, 2021",
       "cells": [
        "TWIGGE GIOVANI Officer",
        "Sell",
        "20.3K",
        "$14.2M"
       ]
      },
      {
       "label": "Feb 7, 2024",
       "cells": [
        "MCKEON BRIAN P Chief Financial Officer",
        "Sell",
        "23.3K",
        "$13.3M"
       ]
      },
      {
       "label": "Nov 10, 2021",
       "cells": [
        "MCKEON BRIAN P Chief Financial Officer",
        "Sell",
        "20.0K",
        "$12.5M"
       ]
      },
      {
       "label": "Nov 5, 2020",
       "cells": [
        "AYERS JONATHAN W Director",
        "Sell",
        "26.6K",
        "$12.5M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=IDEXX+Laboratories%2C+Inc.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "What is IDEXX Laboratories' (IDXX) stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, IDEXX Laboratories' stock price is projected to be $802.54 in 2030 under a base case scenario. The downside projection is $347.35, while the upside projection reaches $1854.25. These figures represent statistical simulation outcomes, not guaranteed price targets."
  },
  {
   "question": "Is IDEXX Laboratories stock a buy right now?",
   "answer": "IDEXX Laboratories is currently rated 'Hold' by Wall Street analysts with a consensus score of 59. While the median analyst target price suggests potential upside, the stock is trading below key moving averages and has seen significant insider selling, indicating caution is warranted."
  },
  {
   "question": "What is the current technical outlook for IDEXX Laboratories (IDXX)?",
   "answer": "The technical outlook for IDEXX Laboratories is bearish, with the stock trading below its 50-day and 200-day moving averages ($546.74 and $592.41) and exhibiting bearish momentum as indicated by its RSI and MACD. Key support levels need to be monitored for potential stabilization."
  },
  {
   "question": "How does IDEXX Laboratories' valuation compare to its sector peers?",
   "answer": "IDEXX Laboratories trades at a premium compared to its Healthcare sector peers. Its P/E ratio of 36.44 and price-to-sales ratio of 9.00 are higher than the sector medians of 31.9 and 3.7, respectively, despite strong profitability metrics."
  },
  {
   "question": "What are the main risks facing IDEXX Laboratories?",
   "answer": "Key risks include substantial insider selling totaling over $75.1 million, a bearish technical trend indicated by price action below key moving averages, and a valuation that is higher than the sector average. These factors suggest potential headwinds for the stock."
  },
  {
   "question": "What is the consensus rating for IDEXX Laboratories stock?",
   "answer": "The consensus rating for IDEXX Laboratories stock is 'Hold', with a consensus score of 59 out of 100. This reflects a balanced view among analysts, with a mix of buy, hold, and some strong buy recommendations."
  },
  {
   "question": "What is the recent earnings performance of IDEXX Laboratories?",
   "answer": "IDEXX Laboratories recently reported a positive earnings surprise for the quarter ending June 2026, beating EPS estimates by 8.65%. This continues a trend of generally positive earnings surprises, although a significant miss occurred in the December 2025 quarter."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "AGL",
    "name": "agilon health, Inc. NYSE",
    "price": "$80.73",
    "change": "+6.46%",
    "url": "https://clearank.com/stock/agl-stock-analysis/"
   },
   {
    "ticker": "MOH",
    "name": "Molina Healthcare Inc. NYSE",
    "price": "$190.86",
    "change": "-1.27%",
    "url": "https://clearank.com/stock/moh-stock-analysis/"
   },
   {
    "ticker": "JNJ",
    "name": "Johnson & Johnson NYSE",
    "price": "$271.22",
    "change": "+0.20%",
    "url": "https://clearank.com/stock/johnson-johnson-jnj/"
   },
   {
    "ticker": "REGN",
    "name": "Regeneron Pharmaceuticals, Inc. NASDAQ",
    "price": "$788.04",
    "change": "-1.00%",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "CAPR",
    "name": "Capricor Therapeutics, Inc. NASDAQ",
    "price": "$8.36",
    "change": "-2.45%",
    "url": "https://clearank.com/stock/capr-stock-analysis/"
   },
   {
    "ticker": "CI",
    "name": "The Cigna Group NYSE",
    "price": "$272.01",
    "change": "+2.45%",
    "url": "https://clearank.com/stock/cigna-group-ci/"
   },
   {
    "ticker": "ILMN",
    "name": "Illumina Inc. NASDAQ",
    "price": "$270.00",
    "change": "-1.42%",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.44",
    "change": "+3.06%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "IONQ vs RGTI Comparison",
    "name": "",
    "url": "https://clearank.com/compare/ionq-vs-rgti/"
   },
   {
    "ticker": "Gold vs Bitcoin Analysis and Targets",
    "name": "",
    "url": "https://clearank.com/compare/gold-vs-bitcoin/"
   },
   {
    "ticker": "LLY vs ABBV Comparison",
    "name": "",
    "url": "https://clearank.com/compare/lly-vs-abbv/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SLVR",
    "text": "Sprott Silver Miners & Physical Silver ETF",
    "url": "https://clearank.com/etf/slvr-etf-analysis/"
   },
   {
    "ticker": "NTES",
    "text": "NetEase, Inc.",
    "url": "https://clearank.com/stock/ntes-stock-analysis/"
   },
   {
    "ticker": "PCAR",
    "text": "PACCAR Inc.",
    "url": "https://clearank.com/stock/pcar-stock-analysis/"
   },
   {
    "ticker": "O",
    "text": "Realty Income Corp.",
    "url": "https://clearank.com/stock/o-stock-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "TON/USD",
    "text": "↑ 12.10%",
    "url": "https://clearank.com/crypto/toncoin-ton-usd/"
   },
   {
    "ticker": "SUI/USD",
    "text": "↑ 11.97%",
    "url": "https://clearank.com/crypto/sui-sui-usd/"
   },
   {
    "ticker": "KAS/USD",
    "text": "↑ 11.85%",
    "url": "https://clearank.com/crypto/kaspa-kas-usd/"
   },
   {
    "ticker": "RENDER/USD",
    "text": "↑ 10.19%",
    "url": "https://clearank.com/crypto/render-render-usd/"
   },
   {
    "ticker": "ZS",
    "text": "↓ 10.06%",
    "url": "https://clearank.com/stock/zscaler-zs/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "A",
    "text": "Agilent Technologies Inc.",
    "url": "https://clearank.com/stock/agilent-technologies-a/"
   },
   {
    "ticker": "DHR",
    "text": "Danaher",
    "url": "https://clearank.com/stock/dhr-stock-analysis/"
   },
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "IQV",
    "text": "IQVIA Holdings Inc.",
    "url": "https://clearank.com/stock/iqvia-iqv/"
   },
   {
    "ticker": "NTRA",
    "text": "Natera, Inc.",
    "url": "https://clearank.com/stock/natera-ntra/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/idxx-stock-analysis.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/idxx-stock-analysis.png",
     "width": "1280",
     "height": "720",
     "caption": "IDEXX Laboratories (IDXX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/idxx-stock-analysis/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/idxx-stock-analysis/",
        "name": "IDEXX (IDXX) Stock Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/idxx-stock-analysis/#webpage",
     "url": "https://clearank.com/stock/idxx-stock-analysis/",
     "name": "IDEXX (IDXX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-19T09:40:34+00:00",
     "dateModified": "2026-09-27T03:00:54+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/idxx-stock-analysis.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/idxx-stock-analysis/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/idxx-stock-analysis/#richSnippet",
     "headline": "IDEXX (IDXX) Stock Forecast & Price Target (2026)",
     "name": "IDEXX (IDXX) Stock Forecast & Price Target (2026)",
     "description": "IDEXX Laboratories, Inc. (IDXX) stock: Healthcare, Diagnostics & Research. $41.0B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-19T09:40:34+00:00",
     "dateModified": "2026-09-27T03:00:54+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "IDEXX Laboratories, Inc.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "IDXX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NASDAQ"
       }
      ],
      "description": "IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice manag",
      "tickerSymbol": "IDXX",
      "sameAs": "https://www.idexx.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/idxx-stock-analysis/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/idxx-stock-analysis.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/idxx-stock-analysis/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "What is IDEXX Laboratories' (IDXX) stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, IDEXX Laboratories' stock price is projected to be $802.54 in 2030 under a base case scenario. The downside projection is $347.35, while the upside projection reaches $1854.25. These figures represent statistical simulation outcomes, not guaranteed price targets."
     }
    },
    {
     "@type": "Question",
     "name": "Is IDEXX Laboratories stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "IDEXX Laboratories is currently rated 'Hold' by Wall Street analysts with a consensus score of 59. While the median analyst target price suggests potential upside, the stock is trading below key moving averages and has seen significant insider selling, indicating caution is warranted."
     }
    },
    {
     "@type": "Question",
     "name": "What is the current technical outlook for IDEXX Laboratories (IDXX)?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The technical outlook for IDEXX Laboratories is bearish, with the stock trading below its 50-day and 200-day SMAs and exhibiting bearish momentum as indicated by its RSI and MACD. Key support levels need to be monitored for potential stabilization."
     }
    },
    {
     "@type": "Question",
     "name": "How does IDEXX Laboratories' valuation compare to its sector peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "IDEXX Laboratories trades at a premium compared to its Healthcare sector peers. Its P/E ratio of 36.44 and price-to-sales ratio of 9.00 are higher than the sector medians of 31.9 and 3.7, respectively, despite strong profitability metrics."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing IDEXX Laboratories?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Key risks include substantial insider selling totaling over $75.1 million, a bearish technical trend indicated by price action below key moving averages, and a valuation that is higher than the sector average. These factors suggest potential headwinds for the stock."
     }
    },
    {
     "@type": "Question",
     "name": "What is the consensus rating for IDEXX Laboratories stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The consensus rating for IDEXX Laboratories stock is 'Hold', with a consensus score of 59 out of 100. This reflects a balanced view among analysts, with a mix of buy, hold, and some strong buy recommendations."
     }
    },
    {
     "@type": "Question",
     "name": "What is the recent earnings performance of IDEXX Laboratories?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "IDEXX Laboratories recently reported a positive earnings surprise for the quarter ending June 2026, beating EPS estimates by 8.65%. This continues a trend of generally positive earnings surprises, although a significant miss occurred in the December 2025 quarter."
     }
    }
   ]
  }
 ]
}